A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.
Ryan Flinn
Advertisement
Articles by Ryan Flinn
AI is poised to transform oncology with innovative tools enhancing diagnosis, treatment, and clinical trials, despite some wariness from clinicians and patients.
In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.
Advertisement
Latest Updated Articles
From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple MyelomaPublished: December 19th 2023 | Updated:
Miles Matter: The Geographic Disparity That Impacts Access to CAR T TherapyPublished: October 13th 2024 | Updated:
Banner Year for Bispecifics as Therapies Advance Into the Community SettingPublished: February 19th 2025 | Updated:
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?Published: November 20th 2024 | Updated:
In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative PatientsPublished: December 9th 2025 | Updated:
Table Multiple Myeloma Trials November 2024Published: November 1st 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
House Republicans Block Vote on ACA Subsidy Extension
2
ICYMI: Highlights From the 2025 ASPC Congress on CVD Prevention
3
Higher BMI, IBD Linked to Hidradenitis Suppurativa Risk via Mendelian Randomization
4
FDA Approves Rucaparib in BRCA-Mutated mCRPC
5
